First Patient Treated with MRTX849, a KRAS G12C Inhibitor

January 2019, first patient in Phase 1/2 clinical trial of MRTX849, a direct KRAS G12C inhibitor, is dosed and shows first clinical data in October 2019.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.